Phase 2 Irritable Bowel Syndrome Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) according to specific medical guidelines called the IOM criteria (confirm with trial site)
- You also have Irritable Bowel Syndrome (IBS) — specifically the type where you experience both diarrhea and constipation that alternate, or mainly diarrhea — diagnosed by a doctor using specific criteria called Rome IV
- You are able to give your informed agreement to take part in the study
- If you are able to become pregnant, you must use effective birth control during the study and for at least six months after the treatment ends
- You are willing to complete online questionnaires and attend follow-up appointments
Who may not be able to join:
- You have taken probiotic supplements in the past eight weeks
- You have taken antibiotics in the past eight weeks
- You are currently pregnant or breastfeeding
- You have certain other gut or serious health conditions, including short bowel syndrome, celiac disease, gallbladder disease, pancreatitis, Crohn's disease, ulcerative colitis, severe heart disease, severe neurological conditions, or liver failure
- You have had surgery on your digestive system within the six months before joining the study
- You have a history of a psychiatric disorder, or issues with alcohol or illegal drug use
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nancy Klimas, MD, Nova Southeastern University, Institute for Neuroimmune Medicine
Phone: 9542622855
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Incidence of Intervention-Related Adverse Events [Safety]; The Measurement of Biomarker Response to an Intervention in the Blood [Efficacy]; level of CRP (C-reactive protein); The pro-inflammatory cytokines level e.g. IL-1, IL-6, and TNF-α; The Symptom Severity Measurement [Efficacy]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.